Stocks News Premium = Support for resolving "Drug Loss", marking related Stocks with support for clinical trials of new drugs overseas.

To eliminate the "drug loss" where new drugs approved overseas are not approved in Japan, the government will support early commercialization through clinical trials and other means. There is a desire to mark related stocks. <M&A is also on the rise> In Japan, the time until new drugs are approved is relatively long, and due to issues with clinical trial costs and profitability, there are cases where Drug Manufacturers do not aim to enter the market. Many new drugs are in this state of drug loss, and patient groups are seeking improvements.

Kabushiki ShimbunApr 18 15:00

Carenet Health Celebrates Official Ribbon Cutting for New Trinidad & Tobago Global Delivery Center

BusinesswireApr 11 23:00

CareNet is ranked and sold amidst a significant overall decline.

CareNet <2150> has ranked (as of 9:32 AM). There is a significant decline. No particularly prominent Sell materials are observed, but since domestic demand companies maintained their value relatively well up until last week and their Stock prices were in a high range, it seems that today there is likely to be some profit-taking Sell during the overall steep drop. Moreover, after the trading closed last weekend, the company announced its share repurchase status. From February 13 to August 29, a repurchase limit of 2.34 million shares, which corresponds to 5.36% of the outstanding shares, has been set, but as of March 31.

Fisco JapanApr 7 08:57

CareNet: Extraordinary Report

EDINETMar 28 13:49 · Announcements

CareNet: Confirmation

EDINETMar 26 15:39 · Announcements

CareNet: Securities Report - 30th Term (2024/01/01 - 2024/12/31)

EDINETMar 26 15:38 · Announcements